“…Similarly, a study using data from the prospective Biologisk Behandling i Dansk Dermatologi (DERMBIO) registry in Denmark demonstrated a trend of lower cumulative incidence of serious adverse events, such as infection, cancer, and cardiovascular events, with ustekinumab compared with adalimumab, etanercept, and infliximab. 4 More recently, the SUSTAIN study, 5 conducted in Germany, reported the efficacy, safety, and tolerability of ustekinumab for the treatment of PsA in routine clinical care from both the physician and patient perspective. At Week 16, efficacy of ustekinumab was rated excellent by 32.3% of physicians, and a further 44.8% of physicians rated it as good.…”